Although previous studies showed a lack of therapeutic benefit for GIP agonists, current studies show that the glucose lowering and weight loss effects of tirzepatide are at least as effective as GLP-1 RAs with a similar adverse effect profile
Improvement of kidney function in patients with chronic kidney disease and severe obesity after bariatric surgery: a systematic review and meta-analysis
The Science: Understanding Tirzepatides Dual Action Tirzepatide is quite similar to semaglutide
India has about 100 million people living with diabetes and obesity each, the company said in a statement
Tirzepatide may be considered for adult patients who are obese (with a body mass index, or BMI, of 30 or greater) or overweight (BMI of 27 or higher) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol
These medications should generally be avoided in patients with a history of pancreatitis